Alpha anomeric bicyclo DNA was invented and developed in the laboratory of Prof. Dr. Christian Leumann at the Department of Chemistry and Biochemistry of the University of Bern, Switzerland. Prof. Leumann is a leading expert in the design, synthesis and characterization of novel backbone modified nucleic acid analogues for antisense- and siRNA-therapy and we are collaborating with his laboratory for the further development of our platform.
About Us
What We Do | Alpha Anomeric
Meet Our Team
Board of Directors
Wolfgang Renner PhD, Président, holds a PhD degree in biotechnology from ETH Zürich since 1995. In the same year he co-founded Cytos Biotechnology AG and was CEO of Cytos until 2011, 9 years of which as a public company. From 2012 to 2017 he served as CEO of Synthena AG and in 2018 he co-founded Alpha Anomeric SAS which he leads as Président. He served as a member of the executive committee and of the foundation council of the Swiss National Science Foundation for 12 years. Wolfgang Renner received several awards, among them the Entrepreneur of the Year Award, the Swiss Economic Award, and the Award for Excellence in Biotech Business.
Dominic Schmidt is General Partner at Advent Life Sciences. Dominic has a background in biochemistry, genomics, molecular oncology, strategy consulting and life science venture capital. Prior to joining Advent, he spent eight years as a Partner in the investment team of Syncona, a publicly listed healthcare investment company. During his time there he was involved in the founding, funding and building of several life science businesses and served on the Boards of Anaveon, Orbit Biomedical (merged with Gyroscope), Gyroscope Therapeutics (acquired by Novartis for up to $1.5 billion), Purespring Therapeutics and Forcefield Therapeutics. After gaining a German Diplom Degree in Biochemistry from the Free University of Berlin and the Max Planck Institute for Molecular Genetics he received a PhD from the Department of Oncology at the University of Cambridge.
Investors
